2 "zero profit drug addition"

In recent years, the implementation of "public hospital drug addition zero profit sales pilot work is gradually carried out. In 2006, development and Reform Commission issued regulations: selling drugs in medical institutions at county level and above, to the actual purchase price based, Shun and no more than 15% of the increase rate pricing, in increase rate on the basis of income for drug addition. In April 2012, the general office of the State Council issued notice "to deepen the reform of the medical and health system in 2012 the main work arrangements", stating that the public hospital reform will cancel the drug addition to and realize the separation of medicine, cut off the interest chain of medicine.

Separation of medicine, drugs "zero slip sales policy in the short term can reduce drug costs, but in the long run does not relieve masses burden of drug costs. Cancel 15% drug addition, while increasing the price of some medical services, for patients, the price is the same. "Zero slip" the purpose is to reduce the rebate, and ease of rebates only this, how to make the drug profits "rationalization", "health", perhaps will be more "fundamental".

3 cancel "the highest price"

In addition to the narcotic drugs and psychotropic substances is still temporarily by the national development and Reform Commission to implement the highest ex factory price and the maximum retail price management, to other government pricing of drugs are to be canceled. No longer the implementation of the highest retail price management, in accordance with the principle of classification management, through different ways by the market price formation. The purpose is to give full play to the market and the government "two hands", the establishment of a scientific and rational price formation mechanism.

In the past in order to curb drug prices unreasonable increases, setting the highest price in a certain extent, play a positive role, now with the Medicare price control ability strengthens gradually, all public hospital drug shall be through the province's centralized bidding and procurement to determine, price competition among pharmaceutical companies becomes more and more fierce. In the control of these three factors, the policy adjustment, generally does not exist in the objective conditions that drug prices rose sharply.

4 "play to control health care costs"

Medicare to pay the total control, referred to as controlling health care costs "refers to the health insurance mechanism on the basis of historical data and the fund's income, to determine the total expenditure of the fund, at the same time, the target decomposition to the medical insurance designated hospitals, in the fixed income support, balance of payments, a slight balance principle, the" balance of retained, cost overruns sharing. " Its purpose is not to increase the overall medical costs at the same time, let the patient get treatment more standardized and reasonable use of limited medical resources, let the people enjoy more high-quality medical services.

The health department in conjunction with the relevant departments in the investigation of drug actual market transaction price on the basis of comprehensive consideration of the health insurance fund and patient factors such as the capacity of the medical insurance payment standard drug. Payment standard in the new Medicare drug formulation before the announcement, the medical insurance fund according to the current policy of temporary pay. Good convergence of health insurance, bidding and purchasing policy coordination, promote medical institutions and retail pharmacies to take the initiative to reduce the purchase price. Designated medical institutions and medical insurance, to pharmacies should submit the drug price department actual purchase price, retail price and purchase quantity of information. Promote the reform of the medical insurance payment, the intrinsic incentive mechanism establish rational administration of medical institutions, reasonable treatment, reduce patient burden.

The price cuts, damage the interests of anyone?

1 upstream pharmaceutical enterprises

Pharmaceutical companies as the upper reaches of the circulation of drugs, each producing, selling a drug, not only spend raw material costs, personnel costs, a variety of business operating costs and pre heavily in R & D expenses and technology transfer purchase costs into expensive. Drug pricing is too low, sometimes not only cost can not be recovered, even no profit at all.

The price is too low to cause the drug shortage problem often staged in recent years. A lot of commonly used drugs, cheap drugs has been difficult to buy, not necessarily the effect as good as new drugs, but low prices lead to manufacturers unprofitable, even can not recover the cost, in desperation, correlation of the tender has been pharmaceutical enterprises have chosen to stop production, resulting in market shortage of medicines, life-saving drugs can not buy.

The pharmaceutical industry depressed for a long time, it will also be lead to the collapse of some small and medium enterprises or mergers, and when large pharmaceutical companies through its own accumulation funds carry over this streak, further acquisitions of small businesses, whether it will form a monopoly in the industry, also never know. If the drug monopoly, the final "victim" or the people who.